SANGAMO THERAPEUTICS INC's ticker is SGMO and the CUSIP is 800677106. A total of 115 filers reported holding SANGAMO THERAPEUTICS INC in Q4 2013. The put-call ratio across all filers is 0.10 and the average weighting 0.7%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2022 | $67,055 | -37.3% | 21,355 | -17.5% | 0.00% | – |
Q2 2022 | $107,000 | +1.9% | 25,900 | +42.7% | 0.00% | – |
Q1 2022 | $105,000 | -82.3% | 18,147 | -80.5% | 0.00% | -100.0% |
Q1 2020 | $592,000 | +72.1% | 92,994 | +126.1% | 0.01% | +250.0% |
Q4 2019 | $344,000 | +84.9% | 41,131 | +138.2% | 0.00% | +100.0% |
Q2 2019 | $186,000 | -37.2% | 17,264 | -33.1% | 0.00% | -50.0% |
Q4 2018 | $296,000 | +36.4% | 25,806 | +78.6% | 0.00% | +100.0% |
Q3 2017 | $217,000 | -93.0% | 14,451 | -95.9% | 0.00% | -92.3% |
Q2 2017 | $3,095,000 | +212.6% | 351,700 | +114.8% | 0.01% | +116.7% |
Q1 2016 | $990,000 | -93.2% | 163,697 | -89.8% | 0.01% | -94.1% |
Q4 2015 | $14,653,000 | +3260.8% | 1,604,890 | +1977.5% | 0.10% | +3300.0% |
Q3 2015 | $436,000 | -96.1% | 77,252 | -89.6% | 0.00% | -97.1% |
Q4 2014 | $11,268,000 | +480.5% | 740,857 | +311.6% | 0.10% | +586.7% |
Q3 2014 | $1,941,000 | -61.2% | 180,000 | -34.9% | 0.02% | -73.7% |
Q1 2014 | $5,001,000 | +80.5% | 276,600 | +38.7% | 0.06% | +58.3% |
Q4 2013 | $2,771,000 | – | 199,465 | – | 0.04% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Alexandria Capital, LLC | 916,153 | $8,740,000 | 1.27% |
Casdin Capital, LLC | 1,080,000 | $10,303,000 | 1.13% |
Rhenman & Partners Asset Management AB | 843,957 | $8,051,000 | 0.94% |
WASATCH ADVISORS LP | 6,437,908 | $61,418,000 | 0.67% |
BB BIOTECH AG | 2,650,000 | $25,281,000 | 0.64% |
Trellus Management Company, LLC | 30,000 | $286,000 | 0.54% |
Opus Point Partners Management, LLC | 33,529 | $320,000 | 0.43% |
SECTOR GAMMA AS | 238,857 | $2,279,000 | 0.36% |
Leisure Capital Management | 37,656 | $359,000 | 0.30% |
Ceeto Capital Group, LLC | 41,000 | $391,000 | 0.29% |